TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC

Inclusion Criteria: 1. Age 18-75 years old; 2. Patients with primary advanced HCC (in accordance with AASLD2018 guidelines for the diagnosis of HCC), without any previous treatment; 3. There is at least one measurable lesion in the liver according to mRECIST criteria, single tumor ≤ 10.0 cm or multiple tumors and tumor burden ≤50% , with portal vein tumor embolus or with extrahepatic metastasis; 4. ECOG score 0-1; 5. Child-Pugh class A; 6. Expected survival time ≥ 3 months; 7. Blood, liver and kidney function meet the following conditions: Neutrophil count ≥ 1.5 × 10 9 /L; Platelet count ≥ 60 × 10 9 /L; Hemoglobin ≥ 90 g/L; Serum albumin ≥ 30 g/L; Bilirubin ≤ 50 umol/L; AST, ALT ≤ 5 times the upper limit of normal, ALP ≤ 4 times the upper limit of normal; Prolongation of prothrombin time not to exceed the upper limit of normal by 6 seconds; Creatinine ≤ 1.5 times the upper limit of normal Exclusion Criteria: 1. Preoperative imaging examination revealed diffuse intrahepatic lesions or invasion, inferior vena cava or primary branch bile duct; 2. Previous history of hepatic encephalopathy, refractory ascites or gastric esophageal varices; 3. There are contraindications to TACE treatment, such as portosystemic shunt, liver flow ablation, significant atherosclerosis; 4. Brain metastases; 5. Hypersensitivity to intravenous contrast agents; 6. Pregnant or lactating women or subjects with family planning within two years; 7. With HIV, syphilis infection; 8. Accompanied by other malignant tumors or suffering from other malignancies within 5 years before enrollment; 9. Allogeneic organ transplant recipients; 10. Severe dysfunction of heart and kidney or other organs; 11. Active severe infection \> grade 2 (NCI-CTC version 4); 12. Suffering from mental and psychological diseases may affect informed consent; 13. Unable to take oral medication; 14. Participated in other drug clinical trials within 12 months before enrollment;